AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
- Data from Phase 3 randomized, placebo controlled trial demonstrates that 46.6 percent of adult patients with moderate to severe psoriasis treated with HUMIRA achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis
- Fingernail psoriasis occurs in up to 55 percent of people living with psoriasis and up to 70 percent of people living with psoriatic arthritis(1)
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?